Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. tissue accumulation and species specific
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • This Year
  • Older

Tissue Accumulation And Species Specific Articles & Analysis

21 news found

Protheragen-ING Provides Comprehensive Microneedle Technology Solutions to Achieve Enhanced Drug Delivery Systems   

Protheragen-ING Provides Comprehensive Microneedle Technology Solutions to Achieve Enhanced Drug Delivery Systems  

In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. With cutting-edge solutions in the field of microneedle technology, Protheragen-ING is on the front lines in this field. As a certified ISO9001 supplier of pharmaceutical ingredients and specialty chemicals, Protheragen-ING keeps ...

ByProtheragen-ING


CD BioSciences Announces Comprehensive Circulatory System Tissue Microarrays

CD BioSciences Announces Comprehensive Circulatory System Tissue Microarrays

CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is pleased to announce the launch of its new line of Circulatory System Tissue Microarrays to the scientific community. This new product line offers researchers a powerful tool to study a wide range of diseases affecting the heart, blood vessels, and spleen. CD BioSciences is committed to ...

ByCD BioSciences


CD Formulation Empowers High-volume Manufacturing of Microspheres

CD Formulation Empowers High-volume Manufacturing of Microspheres

Over the past decade, innovation in the field of microsphere production has reached new heights. Thanks to groundbreaking technology, CD Formulation has enabled mass production services for these versatile particles. Through a cutting-edge approach, CD Formulation is well-prepared to serve the industry by offering efficient and effective solutions for the mass fabrication of microspheres. From ...

ByCD Formulation


CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications

CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has recently launched its new line of PLGA-based drug delivery systems for in vitro and in vivo applications, including biocompatible and biodegradable PLGA nanoparticles with different surface modifications (e.g., COOH groups, methoxy PEG, and PEG-azide). In recent years, the development of nanotechnology ...

ByCD Bioparticles


ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...

ByITM Isotope Technologies Munich SE


Profacgen Updated Its E3 Ligase and Target Proteins Development Services

Profacgen Updated Its E3 Ligase and Target Proteins Development Services

Profacgen has recently updated its E3 Ligase and Target Proteins Development Services, expanding the company’s portfolio of PROTAC development services. The updated services provide scientists with comprehensive advanced platform for their projects. The ubiquitin proteasome system relies heavily on E3 ligases (UPS). As a major modulator of protein homeostasis, UPS is essential in signal ...

ByProfacgen


Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex ...

ByElucid


Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety

Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety

As a consulting and experimental service provider specializing in virology and microbiology, Creative Diagnostics recently introduced CC50/IC50 Assay service with a high level of assay sensitivity and accuracy. The CC50 and IC50 will be plotted using a sigmoidal dose-response curve, and the selectivity index (SI) for each compound is estimated by dividing the CC50 with the IC50. Pharmaceutical ...

ByCreative Diagnostics


New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific approach for HB-300 program in prostate cancer Poster presentations at AACR underscore the versatility of ...

ByHookipa Pharma Inc.


CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing

CD Genomics RNA Diversifies Its RNA Service Portfolio by Adding Whole Transcriptome Sequencing

RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Whole Transcriptome Sequencing to its ...

ByCD Genomics


m5C Profiling Services Now Available by CD Genomics`s RNA Solutions Platform

m5C Profiling Services Now Available by CD Genomics`s RNA Solutions Platform

RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The CD Genomics scientists are ready to help detect various types of RNA via meticulous and integrative approaches. These days, the product manager of CD Genomics announced the m5C profiling services to help researchers deeply ...

ByCD Genomics


Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes

Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes

New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ...

ByUniversal Diagnostics SL


TISSIUM Selected for French Tech 120 Program

TISSIUM Selected for French Tech 120 Program

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been named a French Tech 120 company for the 2021 program. French Tech 120 is a growth-stage program by La French Tech, built to provide government-backed support for the 120 fastest growing companies in France. This is the second year in a row that ...

ByTISSIUM


TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis

TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis

TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...

ByTISSIUM


3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors

3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...

By3DBio Therapeutics


tiakis receives GLP Certificate from Competent Authority

tiakis receives GLP Certificate from Competent Authority

tiakis BIOTECH AG today announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that tiakis test site is able to conduct the archiving of documents related to in-house development ...

Bytiakis BIOTECH AG


Startup Licenses UA-Invented Disruptive Biopsy Device

Startup Licenses UA-Invented Disruptive Biopsy Device

The University of Arizona has licensed the design for a next-generation needle biopsy instrument that utilizes electrosurgery and electrocautery to safely increase tissue sample volumes in minimally invasive biopsy procedures. The licensee is a startup company, Data Driven Diagnostics Sciences Inc., also known as D3Sciences, or D3S. The inventing team includes Dr. Michael Larson, resident ...

ByData Driven Diagnostic Sciences (D3Sciences)


Hockey For Heroes Renews Sponsorship with Celixir

Hockey For Heroes Renews Sponsorship with Celixir

Hockey for Heroes, a supporting charity of Help for Heroes who raise money to help our injured and fallen Heroes, today announces a multi-thousand pound sponsorship renewal with Celixir, a leading British Cell Therapy company. Celixir continues as the charity’s main shirt sponsor for 2018-19, enabling Hockey for Heroes to expand its program to enable injured veterans to take part in ...

ByCelixir plc


Cell Therapy Ltd Grants Japan License To Daiichi Sankyo for Its Heart Regeneration Medicine, Heartcel

Cell Therapy Ltd Grants Japan License To Daiichi Sankyo for Its Heart Regeneration Medicine, Heartcel

Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global ...

ByCelixir plc


Adult Stem Cells

Adult Stem Cells

Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. Adult stem cells support tissue and organ turnover throughout life by maintaining a delicate balance between apoptosis and tissue-specific cellular proliferation and differentiation. Adult stem cells reside ...

ByAelan Cell Technologies

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT